BACKGROUND: Epithelioid sarcoma is a rare soft tissue sarcoma subtype. The response of this disease to chemotherapy is not well described. The aim of this study was to investigate the response rate and progression-free survival in a series of epithelioid sarcoma patients treated with chemotherapy at a single referral center. METHODS: A retrospective search of a prospectively maintained database was made to identify epithelioid sarcoma patients treated with chemotherapy between 1990 and 2009. Radiological response and histological diagnosis were re-reviewed for this study. RESULTS: Twenty-one epithelioid sarcoma patients treated with chemotherapy were identified; follow-up data on palliative chemotherapy was available on 20 of these patients. The median age was 36.5 years (range, 17.4 to 64.8 y) and the male/female ratio was 19:2. Ten patients (50%) were treated with single-agent anthracycline, 9 patients (45%) were treated with a combination therapy (anthracycline and ifosfamide), and 1 patient received trabectedin (5%). Three patients achieved a partial response, 12 had stable disease, and 5 progressed. The median progression-free survival was 29 weeks (95% confidence interval [CI]: 23-35). Seven and 3 patients received second-line and third-line palliative chemotherapy, respectively. The median overall survival from commencing palliative chemotherapy in our series was 51 weeks (95% confidence interval; 29-73). CONCLUSIONS: Systemic chemotherapy provides satisfactory palliation in patients with epithelioid sarcoma. However, this is an aggressive disease, responses to chemotherapy are of short duration and there is a need for more effective novel therapies in the treatment of this condition.
BACKGROUND:Epithelioid sarcoma is a rare soft tissue sarcoma subtype. The response of this disease to chemotherapy is not well described. The aim of this study was to investigate the response rate and progression-free survival in a series of epithelioid sarcomapatients treated with chemotherapy at a single referral center. METHODS: A retrospective search of a prospectively maintained database was made to identify epithelioid sarcomapatients treated with chemotherapy between 1990 and 2009. Radiological response and histological diagnosis were re-reviewed for this study. RESULTS: Twenty-one epithelioid sarcomapatients treated with chemotherapy were identified; follow-up data on palliative chemotherapy was available on 20 of these patients. The median age was 36.5 years (range, 17.4 to 64.8 y) and the male/female ratio was 19:2. Ten patients (50%) were treated with single-agent anthracycline, 9 patients (45%) were treated with a combination therapy (anthracycline and ifosfamide), and 1 patient received trabectedin (5%). Three patients achieved a partial response, 12 had stable disease, and 5 progressed. The median progression-free survival was 29 weeks (95% confidence interval [CI]: 23-35). Seven and 3 patients received second-line and third-line palliative chemotherapy, respectively. The median overall survival from commencing palliative chemotherapy in our series was 51 weeks (95% confidence interval; 29-73). CONCLUSIONS: Systemic chemotherapy provides satisfactory palliation in patients with epithelioid sarcoma. However, this is an aggressive disease, responses to chemotherapy are of short duration and there is a need for more effective novel therapies in the treatment of this condition.
Authors: Anna Maria Frezza; Robin L Jones; Salvatore Lo Vullo; Naofumi Asano; Francesca Lucibello; Eytan Ben-Ami; Ravin Ratan; Pawel Teterycz; Kjetil Boye; Mehdi Brahmi; Emanuela Palmerini; Alexander Fedenko; Bruno Vincenzi; Antonella Brunello; Ingrid M E Desar; Robert S Benjamin; Jean Yves Blay; Javier Martin Broto; Paolo G Casali; Hans Gelderblom; Giovanni Grignani; Alessandro Gronchi; Kirsten Sundby Hall; Olivier Mir; Piotr Rutkowski; Andrew J Wagner; Olga Anurova; Paola Collini; Angelo P Dei Tos; Uta Flucke; Jason L Hornick; Ingvild Lobmaier; Terrier Philippe; Piero Picci; Dominique Ranchere; Salvatore L Renne; Marta Sbaraglia; Khin Thway; Michal Wagrodzki; Wei-Lien Wang; Akihiko Yoshida; Luigi Mariani; Akira Kawai; Silvia Stacchiotti Journal: JAMA Oncol Date: 2018-09-13 Impact factor: 31.777
Authors: Sheri L Spunt; Nadine Francotte; Gian Luca De Salvo; Yueh-Yun Chi; Ilaria Zanetti; Andrea Hayes-Jordan; Simon C Kao; Daniel Orbach; Bernadette Brennan; Aaron R Weiss; Max M van Noesel; Lynn Million; Rita Alaggio; David M Parham; Anna Kelsey; R Lor Randall; M Beth McCarville; Gianni Bisogno; Douglas S Hawkins; Andrea Ferrari Journal: Eur J Cancer Date: 2019-04-05 Impact factor: 9.162
Authors: Samuel V Rasmussen; Jia Xiang Jin; Lissett R Bickford; Andrew D Woods; Felix Sahm; Kenneth A Crawford; Kiyo Nagamori; Hiroaki Goto; Keila E Torres; Angelo Sidoni; Erin R Rudzinski; Khin Thway; Robin L Jones; Alessio Ciulli; Hollis Wright; Melvin Lathara; Ganapati Srinivasa; Kavya Kannan; Paul H Huang; Thomas G P Grünewald; Noah E Berlow; Charles Keller Journal: Clin Transl Med Date: 2022-07
Authors: Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller Journal: Front Oncol Date: 2015-08-17 Impact factor: 6.244
Authors: Angela A Guzzetta; Elizabeth A Montgomery; Heather Lyu; Craig M Hooker; Christian F Meyer; David M Loeb; Deborah Frassica; Kristy L Weber; Nita Ahuja Journal: J Surg Res Date: 2012-05-01 Impact factor: 2.192
Authors: Anneke Alves; Anastasia Constantinidou; Khin Thway; Cyril Fisher; Paul Huang; Robin L Jones Journal: Eur J Cancer Care (Engl) Date: 2021-07-18 Impact factor: 2.328